R&D

[Anonymous]

Percent of TA. So there's more. Mid-level first to go.

 

[Anonymous]

Is it site specific?

 

[Anonymous]

But maybe not the ones they have. Also remember that research is expensive due to material, equipment and maintenance costs.

Discovery research is the least expensive part of R+D. Compared to funding clinical trials, it is nothing.

 

[Anonymous]

Only Inflammation. Onc across all sites. All Heme in TO. Several Dir there too

 

[Anonymous]

Any news on the fate of AWA inflammation or oncology? What about the support groups like pathology, CAR, glass wash/media prep etc..

 

[Anonymous]

Any word on what specific part of Translational Sciences will be affected?

 

[Joe M]

Any word on what specific part of Translational Sciences will be affected?

There will be substantial cuts in Translational Sciences starting with the VPs - similar to the cuts in Onc and Inflammation. We are no longer sending he kids to college, not even community college, therefore CBSS will be cut and any remaining staff will become Covance employees.

 

[Anonymous]

What about protein science?

 

[Anonymous]

What about protein science?

What about CR&D? I assume we won't be affected as much as chemistry is stiil a need for all TAs?

 

[Anonymous]

There will be a 10% reduction in the R&D headcount, across the board reduction.

This is the new fad in Pharma: de-risking. Big pharma wants the early development risk to be absorbed by venture capital who funds the startups. After proof of concept and maybe phase II big pharma is willing to pay more for de-risked concepts. The pharma industry will become healthcare utility type industry-not innovation based. What do you guys think?

 

[Anonymous]

What about CR&D? I assume we won't be affected as much as chemistry is stiil a need for all TAs?

No doubt. CR&D at Amgen has been such a good investment over the years especially compared to protein therapeutics. Modality independence rocks!

 

[Anonymous]

This is the new fad in Pharma: de-risking. Big pharma wants the early development risk to be absorbed by venture capital who funds the startups. After proof of concept and maybe phase II big pharma is willing to pay more for de-risked concepts. The pharma industry will become healthcare utility type industry-not innovation based. What do you guys think?

Check out this excellent op ed piece. It supports what you're saying and sums up the problem with Amgen's myopic snr leadership:

http://www.pharmalot.com/2011/09/op-ed-pharma-layoffs-small-minded-survivors/

 

[Anonymous]

What about CR&D? I assume we won't be affected as much as chemistry is stiil a need for all TAs?

And the EDs of PS-CRD?

 

[Anonymous]

And the EDs of PS-CRD?

Everybody is trying to figure out if they're getting whacked or not. Are you really going to be happy either way? and if not now, when?

 

[Anonymous]

Check out this excellent op ed piece. It supports what you're saying and sums up the problem with Amgen's myopic snr leadership:

http://www.pharmalot.com/2011/09/op-ed-pharma-layoffs-small-minded-survivors/

Great Op-ed. I doubt the execs read it or admit to reading it. But every words therein is true. Another great American industry gone to the graveyard of technology. Just read an article today that NIH will be so budget deprived moving forward that they will only be able to fund 10% of applications and when funds are scarce they will most likely go to established names. So there goes basic scientific discovery.

 

[Anonymous]

No doubt. CR&D at Amgen has been such a good investment over the years especially compared to protein therapeutics. Modality independence rocks!

There is no need for sarcasm..

 

[Anonymous]

This is the new fad in Pharma: de-risking. Big pharma wants the early development risk to be absorbed by venture capital who funds the startups. After proof of concept and maybe phase II big pharma is willing to pay more for de-risked concepts. The pharma industry will become healthcare utility type industry-not innovation based. What do you guys think?

One small detail to be addressed. VCs don't want the risk on the startups, either !

 

[Anonymous]

One small detail to be addressed. VCs don't want the risk on the startups, either !

Oncology & Immunology...... gone.

 

[Anonymous]

CR&D getting RIF at all then?

 

[Anonymous]

Let's beg mike gresser to come back and lead us back to greatness!